Recent content by Chad Lawton

And the other one was me. I didn't predict the company would commit fraud in my opinion. On April 8th, 2022, the company filed an 8-K with the SEC stating that they laid of 30% of their workforce. In the filing they state: "These changes will preserve capital, ensuring that the Company is...

I for sure am. I was prepared to accept the failure of FX-322 but for the company to decide to scratch the entire FX-345 program in one fell swoop as well, especially when no patients even made it to the 90 day testing window based on their first dosed patient in December, absolutely pisses me...

Yea, I’m selling most of my shares. I was not anticipating them discontinuing both FX-322 and FX-345 at the same time. They went from having 3 shots on goal to now only having 1. I took a huge financial loss but also just sad from a tinnitus sufferer’s perspective.

I'm holding long term, I pay no attention to the short term price fluctuations. No insider has bought any shares in the last year and a half.

There really isn't much to elaborate on. The stock has had dozens and dozens of 10% up and down days over the last 2 years for no reason at all. The stock ran up over 100% in a month and people are reading into a 10% drop.

No.

It means the stock went down 10% today; it's the nature of small market cap, no revenue generating biotech. The study's primary completion date was on December 30th, so I'm sure they've unblinded sometime in the last month so there are probably a select few at FREQ that already know that results.

Really depends what share price we end up at right before data drop. I think it's reasonable that we could double up overnight to anywhere from $10 to $20 on good data. If FX-322 proves efficacy, it revalidates their entire platform and it's game on from there. If FX-345 also comes back with...

Looks like you may benefit from FX-345 based on where your notch is and if FX-345 penetrates as deeply as they are predicting. As for Viagra & hearing loss, I can't say I know anything about it.

Correct, they haven't changed the formulation for FX-322. You may look at it as "but only showed improvements in word recognition scores" but that is not how the audiology community & FDA sees it. FDA has already said they will accept word recognition improvements as the primary trial endpoint...

Its completely fair to be skeptical. Just keep in mind that the brain can do some weird and amazing things. I'm not going to discount the chance of that guy's improvement actually being from the drug simply because it occurred seemingly instantly. It very well could be the case that the cochlear...

That is the whole point of FX-345. Its an improvement on FX-322 in that their goal is to get the compounds deeper into the cochlea so that they can reach more hair cells and potentially see a more efficacious response.

Purely speculation on my part but to me it seems that is sort of a sweet spot for FX-322 responders. The biggest factors at play are the cochlear penetration of the drug and how the overall functionality of the subjects cochlea is before treatment. Since FX-322 only reaches the higher...

Yes, that is actually a pretty accurate description of what some of the science has found is occurring. Tuning out the noise: Limbic-auditory interactions in tinnitus When I say the brain is "rewiring", I'm referring to the gating mechanisms you mention. It seems that those who suffer from...

Administration of FX-322 didn't reverse his disease instantly, it occurred approximately 30 days after treatment. 4 weeks is not an unreasonable amount of time for immature hair cells to start to communicating with the brain. Who is to say the hair cells didn't start working sooner than 30 days...